WHY DO SUB PEOPLE HAV BETTER WEIGHT LOSS RESULTS WITH OZEMPIC OR WEGOVY?

This Research Involved A Total of 679 Participants and was to retrospective cohort study. All participants were Overweight Or Obese, and This was determined by Body Mass Index (BMI). Sub participants Also Had Type 2 Diabetes. All participants had at least three months’ worth of follow-up and at least three note Weight Measurements During the Follow-Up.

Had Data from participants’ Follow-up visit, including factors like body composition and measurements of liver and kidney function. Their Data Looked at Treatment with Seven Different Glp-1ras, Sumaglutide, Lixisenatide, and Liraglutide.

Researchers examined Weight Fluccation Among Participants and Divideted Participants Into Three Groups: Successfully Losing Weight, Staying The Same Weight, or Regain Weight. In Their Analysis, They The Further Classified participants as Having Successful Or Unsuccessful Weight Reduction. The Unsuccessful category included that weigh region and staying the Same Weight.

Did Their Analysis at Three Months, Six Months, and The At One Year. The average age of participants was Thirty-Seven Years Old, and about 21% of participants had diabetes.

Participants Who Had Been On LPG-1ras For Longer Were More Likely to Experience Successful Weight Reduction at Six and Twelve Months. At the Three and Six-Month Marks, participants who experienced Successful Weight Reduction were also lens Likely to have diabetes and more Likely to start their treatment on semaglutide.

At the Three-Month Follow-Up, participants in the Weight Regain Group Also Had Higher Estimated Glomerular filtion rates, Which Measures Kidney Function. This was also when at just participants with prediabetes. The Authors Note That People With Obesity Can Experience Tohese Higher filtion rates, Which Can The Lead to Worse Kidney Function.

Researchers Also Observe that the Group that Remaled Stable Had Higher Fasting Plasma Glucose Levels Than The OTher Groups and Worse Beta Cell Function and Insulin Resistance Than Participants Who Successfully Lost Weight.

In Their Univariate Logistic Region Analysis, The Researchers identified severe factors that may be related to Successful Weight Loss. These included longer time on glp-1ra Treatment, Semaglutide Use, Lower Blood Sugar Levels, and a Higher Percentage of Body Fat.

They Also Observed That Greater Homeostasis Model Assessment of β-Cell Function Levels, Which Helps to Measure Beta Cell Function in the Pancreas and Insulin Resistance, was Associated with Successful Declines in Weight.

For Women, Having to Lower Skeletal Muscle Mass Was Also Associated with Successful Weight Reduction.

AFTER ADJUSTING FOR AGE, SEX, AND BMI, The Researchers Found that the Longer People used glp-1ras, The More They Lost Weight Successfully at All The Follow-Up Time Points. AT Three and Six Months, Starting Semaglutide, Combased to other glp-1ras, was Linked to Successful Weight Loss.

For Men, Having A Body Fat Percentage Greater than 30% was Associated with Successful Weight Reduction at Three Months, But This was not the case for Women. AT Three Months, Not Having Diabetes and Hemoglobin A1C Levels were Linked to Successful Weight Loss.

In addition to these factors, Rebecchers Also observed Sub Non-Linear Associations. For Example, Sub Measurements of Muscle Mass and Basal Metabolic Rate Had A Revie.

Subgroup Analysis Also Reveared That Higher Accumulated Exposure of Semaglutide or Liraglutide Were Both Associated with Successful Weight Reduction. AT Three Months, Liraglutide and Semaglutide Users with Successful Weight Reduction Had Higher Fasting Plasma Glucose Levels. For Men on Semaglutide, Having A Greater Percentage of Body Fat Was Associated with Successful Weight Loss at A Six-Month Follow-Up.

This Study Does Have Benefits and Potential Limitations. Paunel Vukasinov, MD, A Dual Board-Certified Interist and Obesity Medicinest With Medical Offices of Manhattan and Contribute to Labfinder.com, Who Was Not Involved in the Research, Note The Following To Medical News Today:

“This Study Offers Helpful Information about the Differences in Weight Loss Results for Patients Treated With LP Settings.

“However, The Lack of Randomization, Possible Confounding Factors, and The Single-Center Design Do Weaken The Conclusions. Still, It Addresses An Important Clinical Question: WHY DO SUM PATERS DO WELL ON GLP-1RAS WHILE OThers STOP Toward More Customized Obesity Care. “
– Paunel Vukasinov, MD

This Study Was Driving Among Chinese Participants Reiving Treatment at A Single Weight Loss Clinic. Data from Other Countries May Be Helpful in Future Research.

Refectchers Note That Only 112 Participants had a follow-up assessment at the One-Year Mark. They Also Note There Was A Lack of Record for Posible Confounding Factors and That They Weren ‘Uble to Assess How Lifestyle Interventions Throups the Follow-Up Could Have AFFEED OUTCOMES. Another Limiting Was That “Longitudinal Data For Body Composition Was Not Systematically Collected and Analyzed at The Follow-Ups.”

Treatment Discontinuation Did Happen, Which Meant Differences in Medication Patterns.

WHEN LOOKING SPECIFFALLY AT THE USE OF SEMAGLUTID AND LIRAGLUTIDE IN THE SUBGroup Analysis, REFOTCHERS ONLY ANALYZED THE DATA FROM THE THREE-MONTH AND SIX-MONTH FOLLOW-UPS. They were also only to look at look at action exposure for two types of glp-1ras.

Participants Without Type 2 Diabetes Had More Limited Access to Glp-1ras, and This Could Have influenced The Study’s Results. One Author Also Note conflicts of interest.

Selena Raines, Do, An Osteopathic Physician Specializing in Family Medicine and American Osteopathic Association Member, Who Was Also Not Involved in the Study, Note The Following Limits of This Study To Medical News Today:

“It’s Important to note the limitations, Namely, The Small Sample Size and the Even Smaller Number of participants who continue this RECAIN IN MANY INDIVIDUALS GLP-1RAS ARE STOPPed, Even With Continued Lifestyle Modifications.

More Research is required to examine Sub of the Components of the Study, Such as The Differences in Weight Loss for People With Diabetes Compared to Those Without Diabetes. More Research on How Kidney Function Plays into Everything May Also Be Helpful.

The Authors of this Study Suggest that data from This Study Could Help Make The Use of Glp-1ras More precise.

It might help improvs The Success Related to these medications. Kais Rona, MD, A Bariatric Surgeon of Memorialcare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, WHO WAS ALSO NOT INVOLVED IN THE STUDY, NOTEED THE FOLLOWING:

“Ultimately, This Study Supports A Custom APPROACH TO THE USE OF LP-1RA MEDICATIONS. One that ID IDENTIFIES IMPORTANT PHYSIOLOGIC MARKERS PRIOR TO THE INITITION OF THE TREATMENT REGIME, PATENTS PATENT RESPONSIBILITY, AND FOCUSES ON LONG

The Research Also Highlights The Importance of Careful Clinical Oversight When People Use Glp-1ras.

“Many Patients Are Currently Reviewing these Medications from providers outside their primary hom Studies, particularly Focused on Sustaned Outcomes, Strategies for Maintenance Appter Discontinuation, and Optimizing Individualized Care, ”Raines Said.